CoChat
Sign Up
Cited by 144Computational Drug Discovery MethodsHistorical Medical Research and TreatmentsPharmaceutical Economics and Policy

The DOI matches its Crossref record; 198 of the 202 references it cites were found in a registry or an index.

A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

Open access
Pillaiyar, Thanigaimalai, Meenakshisundaram, Sangeetha, Manickam, Manoj, Sankaranarayanan, Murugesan·2020·European Journal of Medicinal Chemistry
DOI 10.1016/j.ejmech.2020.112275PMC PMC7156148
Open this paper in CoChat — free accountOpen PDF

Abstract

Drug repurposing is a strategy consisting of finding new indications for already known marketed drugs used in various clinical settings or highly characterized compounds despite they can be failed drugs. Recently, it emerges as an alternative approach for the rapid identification and development of new pharmaceuticals for various rare and complex diseases for which lack the effective drug treatments. The success rate of drugs repurposing approach accounts for approximately 30% of new FDA approved drugs and vaccines in recent years. This review focuses on the status of drugs repurposing approach for various diseases including skin diseases, infective, inflammatory, cancer, and neurodegenerative diseases. Efforts have been made to provide structural features and mode of actions of drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2020.112275

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 202 references

4 of the 202 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. Gilbert, 2003, Rebuilding big pharma’s business model, in vivo, The Business Med. Rep., 21, 73
  2. Broughton, 2012, Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study, BMC Gastroenterol., 12, 36, 10.1186/1471-230X-12-36 · DOI
  3. Regnard, 2011, vol. 42, 319
  4. Pagan, 2016, vol. 6, 503

Cited by

Sorted by citations

Items 101–144 of 144

Related

See all

Metadata

Authors
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M.
Affiliations
  • University of Bonn (DE)
  • PSG INSTITUTE OF TECHNOLOGY AND APPLIED RESEARCH (IN)
Corresponding author
Pillaiyar, Thanigaimalai
ORCID
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2020-06
Volume
195
Pages
112275
ISSN
0223-5234 (ISSN-L)
DOI
10.1016/j.ejmech.2020.112275
PMC
PMC7156148
OpenAlex
W3013498471
Cited by
140
References
202
Citations by year
2026: 13 · 2025: 25 · 2024: 18 · 2023: 25 · 2022: 26 · 2021: 15 · 2020: 17
FWCI
1.91
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Medicinal Chemistry (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • PSG
  • PSG Institute of Technology and Applied Research
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
drug repurposing, marketed drugs, rare diseases, skin diseases, infectious diseases, inflammatory diseases, cancer, neurodegenerative diseases, structural features, mechanism of action
MeSH terms
Animals, Chemistry, Pharmaceutical, Humans, Drug Discovery, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review